These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 20547017)

  • 1. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
    Filipponi P; Pedetti M; Fedeli L; Cini L; Palumbo R; Boldrini S; Massoni C; Cristallini S
    J Bone Miner Res; 1995 May; 10(5):697-703. PubMed ID: 7639104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M; Quarta L; Calcagnile F; Quarta E
    Adv Ther; 2010 May; 27(5):314-20. PubMed ID: 20526703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ; Laitinen K; Patronen A; Puolijoki H; Seppänen J; Pylkkänen L; Aranko SM; Sairanen S; Blåfield H; Rekiaro M; Väisänen K; Kormano M; Mäkinen L; Salmi J; Ala-Kaila K; Perttilä J; Vesterinen K; Koivunoro K;
    Osteoporos Int; 2002 Dec; 13(12):937-47. PubMed ID: 12459936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
    Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT; Komulainen M; Kröger H; Honkanen R; Jurvelin J; Puntila E; Heikkinen AM; Alhava E; Saarikoski S
    Osteoporos Int; 1998; 8(1):32-8. PubMed ID: 9692075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Christiansen C
    Maturitas; 2005 Feb; 50(2):78-85. PubMed ID: 15653003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T; Heikkinen AM; Mahonen A; Kröger H; Komulainen M; Saarikoski S; Honkanen R; Mäenpää PH
    J Bone Miner Res; 2000 Feb; 15(2):315-21. PubMed ID: 10703934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S; Limpaphayom KK
    J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.